Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT02232490 is registered in ClinicalTrials.gov with Immunitor LLC as lead sponsor.

NCT NCT02232490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02232490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Immunitor LLC
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2015
Completion date
December 31, 2019
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hcc, hepatocellular carcinoma, liver cancer